Subject(s)
Acoustics , Carcinoma, Krebs 2/pathology , Animals , Carcinoma, Krebs 2/therapy , Female , Magnetic Resonance ImagingABSTRACT
The efficiency, acute and delayed toxicities of different radio-chemotherapeutic combinations were assessed on an in vivo model (Krebs II ascitic carcinoma grafted to female Swiss mice). Mice were given whole abdomen irradiation (WAI) 2.5 to 10 Gy as a single dose (WAI). CDDP was given intraperitoneally at 0.5 to 4 mg/kg dose level, 12 hr before or after WAI. There was a relationship between dose of CDDP and increase of life span (ILS) of mice. However, WAI did not increase the life span. When a single dose of 2 mg/kg CDDP was given prior to a 2.5 Gy WAI, the ILS reached 47%. By contrast, it was only 37% when treatment sequence was reversed. When the WAI dose level was increased to 5 Gy, the ILS was not increased. The jejunal crypt cell number, determined 3 days after the last treatment, was not modified, regardless of the treatment sequence. There was no delayed renal toxicity. The study on the Krebs II ascites model confirms the tumor cell therapeutic potentiation without exacerbation of normal tissue damage.
Subject(s)
Carcinoma, Krebs 2/therapy , Organoplatinum Compounds/adverse effects , Animals , Combined Modality Therapy , Female , Intestinal Mucosa/drug effects , Intestinal Mucosa/radiation effects , Jejunum/drug effects , Jejunum/radiation effects , Kidney/drug effects , Kidney/radiation effects , Mice , Radiotherapy DosageABSTRACT
The results of the study of the antiproliferative effect of swine leukocyte interferon and of an inhibitor of interferon effect in experimental mice with transplanted Krebs-2 ascitic carcinoma cells are presented. The interferon inhibitor exerted antiproliferative effect similar to that of native swine interferon. Combined use of swine interferon and interferon inhibitor did not lead to summation of the antiproliferative effect of these preparations.
Subject(s)
Interferon Type I/antagonists & inhibitors , Interferon Type I/therapeutic use , Animals , Carcinoma, Krebs 2/pathology , Carcinoma, Krebs 2/therapy , Cell Count/drug effects , Cell Transformation, Neoplastic/drug effects , Drug Evaluation, Preclinical , Drug Therapy, Combination , Mice , Neoplasm Transplantation , Swine , Time FactorsABSTRACT
To immunize CC57BR mice a suspension of live cells of Krebs-2 ascites tumour was administered intradermally into the tail partially amputated afterwards. The growth of the tumour transplanted intraperitoneally was inhibited by 23% only after twofold immunization. Single immunization with tumour cell incubated with the cattle liver RNA preparation in conjunction with intraperitoneal administration of RNA following tumour transplantation inhibited its growth by 43--53%, while twofold administration by 84--88%. The high polymeric fraction of the preparation enhanced the immunization effect to the same measures the initial overall preparation. The treatment of the preparation with RNAase and partial depolymerization of RNA in the course of isolation resulted in the activity loss. It is concluded that the capacity of the RNA preparation for stimulating antitumour immunity is due to high polymeric fraction of RNA.
Subject(s)
Adjuvants, Immunologic , Carcinoma, Krebs 2/immunology , RNA/immunology , Animals , Carcinoma, Krebs 2/therapy , Cattle , Drug Evaluation, Preclinical , Immunity/drug effects , Immunization , Liver/immunology , Mice , Mice, Inbred C57BL , Neoplasm Transplantation , RNA/isolation & purificationABSTRACT
The growth of Krebs-2 carcinoma in BCG-prevaccinated virgin female C57BL/6, CC57BR/M, and C3Hf mice was studied in relation to the number of living mycobacteria in the organism. When the number of mycobacteria was high, tumor growth was stimulated. After the bacteria were eliminated, tumor growth was inhibited. The effect of BCG was based, on the one hand, on the diversion of effector cells, presumably macrophages, responsible for tumor defense and, on the other hand, on the activation of the pool of these cells. The conclusions were reached that high doses of BCG may be dangerous in human cancer immunotherapy and that patients predisposed to neoplastic disease should be revaccinated with BCG.
Subject(s)
BCG Vaccine/administration & dosage , Carcinoma, Krebs 2/therapy , Animals , Carcinoma, Krebs 2/immunology , Carcinoma, Krebs 2/microbiology , Dose-Response Relationship, Immunologic , Female , Immunity , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Mycobacterium bovis/isolation & purificationABSTRACT
The effect of BCG vaccine on the growth of imtransplants of Krebs-2 carcinoma in mice was studied. The simultaneous injection of BCG and tumor cells either inhibited tumor growth (BCG given in admixture with tumor cells) or stimulated it (BCG injected contralateral to the tumor transplantation site). The BCG dose was directly related to the effect. Tumor growth was also stimulated by the ip injection of starch or liquid paraffin. In these experiments, the BCG effect was attributed to the redistribution of cells involved in nonspecific and specific tumor resistance. Shortly after BCG prevaccination, particularly when BCG doses were high and mice were susceptible to vaccine infection, BCG was either without effect or stimulated tumor growth; later, however, tumor growth was inhibited regardless of the BCG dose and the injection site of the BCG. The effect of BCG prevaccination was suggested to be due to: 1)the distraction of macrophages and T-lymphocytes to defend the host against the multiplying mycobacteria, and 2)the activation of the pool of these cells that become capable to participate in antitumor resistance after mycobacteria elimination.
